Visara Licenses Neurotrophic Keratitis Therapy, Expanding Ophthalmology Pipeline
Event summary
- Visara secures exclusive worldwide rights (excluding Greater China) to VIS-102 (HT006.2.2), a modified recombinant human nerve growth factor therapy for neurotrophic keratitis.
- VIS-102 is designed for convenience, with refrigerated, ready-to-use single-dose units, potentially simplifying patient administration.
- Phase 1b data showed 50% complete corneal healing in the highest dose cohort after an 8-week course, compared to 14% in the vehicle control group at Week 4.
- Visara plans to develop VIS-102 as its second clinical-stage program, expanding beyond retinal vascular disease into ocular surface disease.
The big picture
Visara’s licensing deal reflects a strategic shift into ocular surface disease, complementing its existing focus on retinal vascular diseases. This move aligns with NovaBridge’s model of building focused franchises around differentiated innovation, aiming to create long-term value in the ophthalmology sector. The deal underscores the growing emphasis on convenience and patient-centric design in biologic therapies.
What we're watching
- Clinical Progress
- Whether VIS-102 can replicate Phase 1b results in larger, more diverse patient populations and secure regulatory approval.
- Pipeline Diversification
- How Visara balances development of VIS-102 alongside its existing retinal vascular disease program, VIS-101.
- Commercial Strategy
- The pace at which Visara can establish VIS-102 as a differentiated treatment in the neurotrophic keratitis market.
Related topics
